Cassava Sciences (NASDAQ:SAVA) traded higher in the premarket on Tuesday after the Alzheimer’s drug developer received its only buy rating on Wall Street as H.C. Wainwright upgraded the stock, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results